TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27809785

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 27809833

Group type: EXPERIMENTAL
Intervention: Unilateral cataract extraction with intraocular lens implantation
Number of subjects: 53
Study: 27810712

Group type: EXPERIMENTAL
Intervention: Polysomnographic sleep parameters (PSG)
Number of subjects: 54
Study: 27810720

Group type: EXPERIMENTAL
Intervention: Recovery Index - a latent measure assessing impact of illness on functioning and QOL
Number of subjects: 0
Study: 27810876

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients (homozygotes and heterozygotes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis homozygotes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis heterozygotes
Number of subjects: 30
Study: 27811070

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 µg
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 27811151

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA) alone in females
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA) combined with myocardial perfusion imaging (CTP) in females
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA) alone in males
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA) combined with myocardial perfusion imaging (CTP) in males
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Incremental value of CTP over CTA alone in females
Number of subjects: 381

Group type: COMPARATOR
Intervention: Prevalence of flow-limiting CAD in males
Number of subjects: 381

Group type: COMPARATOR
Intervention: Prevalence of flow-limiting CAD in females
Number of subjects: 381
Study: 27811203

Group type: EXPERIMENTAL
Intervention: hs-cTnI concentration < limit of detection (LoD) at presentation in the derivation cohort
Number of subjects: 3845

Group type: EXPERIMENTAL
Intervention: hs-cTnI concentration < limit of detection (LoD) at presentation in the validation cohort
Number of subjects: 3845

Group type: EXPERIMENTAL
Intervention: hs-cTnI concentrations <99th percentile at presentation
Number of subjects: 3845
Study: 27811504

Group type: EXPERIMENTAL
Intervention: Observation after nephrectomy without adjuvant chemotherapy
Number of subjects: 116
Study: 27812090

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical algorithms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical and first-line laboratory features
Number of subjects: 0
Study: 27812547

Group type: EXPERIMENTAL
Intervention: Inhaled sodium nitrite at doses of 45 mg and 90 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Inhaled sodium nitrite
Number of subjects: 36

Group type: COMPARATOR
Intervention: Inhaled nitric oxide
Number of subjects: 36
Study: 27813195

Group type: EXPERIMENTAL
Intervention: D-mannose powder 1.5 grams twice daily for 16 weeks
Number of subjects: 22
Study: 27814297

Group type: EXPERIMENTAL
Intervention: [18F]FDDNP PET
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CSF Aβ levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of [18F]FDDNP binding
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CSF tau levels
Number of subjects: 30
Study: 27814346

Group type: EXPERIMENTAL
Intervention: Propranolol 0.1% eye micro-drops
Number of subjects: 23
Study: 27814377

Group type: EXPERIMENTAL
Intervention: 7.5 μg of the homologous strain vaccine re-immunized at 6-months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 μg alum-adjuvanted clade 2, A/Indonesia vaccine re-immunized at 22-months
Number of subjects: 0

Group type: COMPARATOR
Intervention: 30 μg alum-adjuvanted A/Vietnam vaccine
Number of subjects: 0
Study: 27814457

Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients (BD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 28
Study: 27814689

Group type: EXPERIMENTAL
Intervention: Nursing home residents
Number of subjects: 132

Group type: COMPARATOR
Intervention: Nursing home staff
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Residents without dementia
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Nursing home residents during outbreaks
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Overall ARI episodes
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Specific viruses in residents
Number of subjects: 132

Group type: COMPARATOR
Intervention: Specific viruses in staff
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Outbreak cases
Number of subjects: 132
Study: 27814709

Group type: EXPERIMENTAL
Intervention: Acupoint herbal plaster treatments (4 applications using moxibustion technique)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Acupoint herbal plaster treatments
Number of subjects: 23
Study: 27814712

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 500
Study: 27814717

Group type: EXPERIMENTAL
Intervention: Differentially methylated CpG probes associated with COPD
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Weighted gene coexpression network analysis (WGCNA)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Differentially methylated CpG sites
Number of subjects: 362
Study: 27814739

Group type: EXPERIMENTAL
Intervention: CTO-PCI
Number of subjects: 29
Study: 27814763

Group type: EXPERIMENTAL
Intervention: Intervention (IPTp-SP)
Number of subjects: 31493

Group type: COMPARATOR
Intervention: Control (Counterfactual)
Number of subjects: 31493

Group type: EXPERIMENTAL
Intervention: Antenatal care utilization
Number of subjects: 31493

Group type: EXPERIMENTAL
Intervention: Cost of delivering three doses of SP
Number of subjects: 31493
Study: 27815268

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 2428
Study: 27815290

Group type: EXPERIMENTAL
Intervention: Eversense implantable CGM sensor
Number of subjects: 71
Study: 27815383

Group type: EXPERIMENTAL
Intervention: JE-CV booster
Number of subjects: 47
Study: 27815401

Group type: EXPERIMENTAL
Intervention: Single-chain recombinant tissue plasminogen activator (rtPA)
Number of subjects: 1004
Study: 27815915

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week for 16 weeks
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1212
Study: 27816492

Group type: EXPERIMENTAL
Intervention: Tremelimumab (3.5 and 10mg/kg i.v.) every 4 weeks for 6 doses, followed by 3-monthly infusions until off-treatment criteria were met.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tremelimumab in combination with subtotal radiofrequency ablation or chemoablation.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tremelimumab in combination with tumor ablation.
Number of subjects: 32
Study: 27817208

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 4725

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4725
Study: 27817951

Group type: EXPERIMENTAL
Intervention: INTUITY rapid deployment aortic valve replacement (RDAVR) system
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: INTUITY RDAVR
Number of subjects: 839
Study: 27820636

Group type: EXPERIMENTAL
Intervention: Causative mutations identified by sequencing
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Insertions and deletions
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Mutations predicted to affect splicing
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Single point mutations
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Genotype-phenotype correlation analysis
Number of subjects: 79
Study: 27820654

Group type: EXPERIMENTAL
Intervention: Overfeeding diet with 3% protein
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overfeeding diet with 75% carbohydrate
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fasting vs Overfeeding
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Higher urinary epinephrine concentrations during fasting
Number of subjects: 64
Study: 27820947

Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in 1990 to 1999
Number of subjects: 14566

Group type: EXPERIMENTAL
Intervention: Survivors with leukemia
Number of subjects: 14566

Group type: EXPERIMENTAL
Intervention: Survivors with osteosarcoma
Number of subjects: 14566

Group type: EXPERIMENTAL
Intervention: Survivors with chronic health conditions, demographic characteristics, and health habits
Number of subjects: 14566

Group type: COMPARATOR
Intervention: Survivors diagnosed in 1970 to 1979
Number of subjects: 14566
Study: 27821091

Group type: EXPERIMENTAL
Intervention: Influenza-related outpatient visits in patients <65 years
Number of subjects: 35000000

Group type: EXPERIMENTAL
Intervention: Influenza-related outpatient visits in children 5-17 years and adults 18-64 years
Number of subjects: 35000000

Group type: EXPERIMENTAL
Intervention: Influenza-related outpatient visits in children <5 years
Number of subjects: 35000000

Group type: EXPERIMENTAL
Intervention: Influenza-related OM visits
Number of subjects: 35000000

Group type: EXPERIMENTAL
Intervention: Influenza-attributable outpatient visits in infants <2 years and toddlers aged 2-4 years
Number of subjects: 35000000

Group type: EXPERIMENTAL
Intervention: Influenza-related respiratory visits in seniors 65 years and older
Number of subjects: 35000000

Group type: COMPARATOR
Intervention: UTI visits as a negative control
Number of subjects: 35000000

Group type: EXPERIMENTAL
Intervention: Overall outpatient care for respiratory illness attributable to influenza
Number of subjects: 35000000
Study: 27821384

Group type: EXPERIMENTAL
Intervention: 3 20-minute hand massages (experimental)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 3 20-minute hand holdings (active control)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 3 20-minute rest periods (passive control)
Number of subjects: 79
Study: 27821451

Group type: EXPERIMENTAL
Intervention: Auranofin, 6 mg orally daily for 7 days
Number of subjects: 0
Study: 27821473

Group type: EXPERIMENTAL
Intervention: Primary mechanical thrombectomy (MT)
Number of subjects: 131

Group type: COMPARATOR
Intervention: IV thrombolysis (IVT) followed by mechanical thrombectomy (MT)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Comparison of MT vs IVT+MT
Number of subjects: 131
Study: 27821717

Group type: EXPERIMENTAL
Intervention: Energy restriction (~20% reduced intake of energy from food)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced energy expenditure due to physical exercise (combined endurance- and strength-training)
Number of subjects: 0
Study: 27822376

Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided high-intensity focused ultrasound (HIFU) treatment
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Quality of life and symptom outcome assessment using the uterine fibroid symptom and quality of life questionnaire
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Safety assessment through reported adverse events
Number of subjects: 107
Study: 27822454

Group type: EXPERIMENTAL
Intervention: Robotic surgery for thoracic oncology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 0
Study: 27822900

Group type: EXPERIMENTAL
Intervention: FMISO intratumour distribution
Number of subjects: 10
Study: 27822929

Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Number of subjects: 553
Study: 27825292

Group type: EXPERIMENTAL
Intervention: Acute spondylolysis treatment
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 121
Study: 27825340

Group type: EXPERIMENTAL
Intervention: Nurse-led telecoaching programme consisting of 5 monthly telephone sessions of +/- 30 min
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Nurse-led telecoaching programme
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Provider views on telecoaching
Number of subjects: 287
Study: 27825364

Group type: EXPERIMENTAL
Intervention: MR-proADM biomarker evaluation
Number of subjects: 67
Study: 27825374

Group type: EXPERIMENTAL
Intervention: Talinolol
Number of subjects: 55
Study: 27825382

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: MAL1C-like antibodies
Number of subjects: 276
Study: 27825636

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally per day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 26
Study: 27825780

Group type: EXPERIMENTAL
Intervention: Early-onset bipolar disorder (EOB)
Number of subjects: 555

Group type: COMPARATOR
Intervention: Late-onset bipolar disorder (LOB)
Number of subjects: 555
Study: 27826345

Group type: EXPERIMENTAL
Intervention: Early Surgery
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional Treatment
Number of subjects: 76
Study: 27826691

Group type: EXPERIMENTAL
Intervention: DRD2 C957T polymorphism T-allele carriers
Number of subjects: 128

Group type: COMPARATOR
Intervention: DRD2 C957T polymorphism
Number of subjects: 128
Study: 27827322

Group type: EXPERIMENTAL
Intervention: Peri-muscular adipose tissue cross-sectional area in women with PCOS
Number of subjects: 68

Group type: COMPARATOR
Intervention: Adiponectin and thigh subcutaneous adipose tissue in women without PCOS
Number of subjects: 68
Study: 27827324

Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Early cerebral infarcts
Number of subjects: 413
Study: 27828822

Group type: EXPERIMENTAL
Intervention: Fluorescence imaging (FI) using indocyanine green (ICG) at 0.25 mg/kg IV-injected intraoperatively
Number of subjects: 14
Study: 27828943

Group type: EXPERIMENTAL
Intervention: Selective PI3Kγ inhibitor (IPI-549)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27829180

Group type: EXPERIMENTAL
Intervention: Fluid challenge
Number of subjects: 40
Study: 27829397

Group type: EXPERIMENTAL
Intervention: Community-based behavioral intervention to reduce sugar-sweetened beverage consumption
Number of subjects: 0
Study: 27829430

Group type: EXPERIMENTAL
Intervention: Antibodies to pRBC surface antigens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total IgG to pRBCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opsonizing antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibodies to merozoite antigens and non-placental-binding IEs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibodies to placental-binding infected erythrocytes
Number of subjects: 0
Study: 27829511

Group type: EXPERIMENTAL
Intervention: Infants infected with HIV
Number of subjects: 3554

Group type: EXPERIMENTAL
Intervention: Infants exposed to but uninfected with HIV
Number of subjects: 3554

Group type: COMPARATOR
Intervention: Unexposed infants
Number of subjects: 3554
Study: 27830157

Group type: EXPERIMENTAL
Intervention: Technology Enabled Health Coaching Program
Number of subjects: 0
Study: 27830207

Group type: EXPERIMENTAL
Intervention: Interactive Binocular Treatment (I-BiT™) with patching
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group with patching only
Number of subjects: 50
Study: 27830935

Group type: EXPERIMENTAL
Intervention: Video-recorded measures of behavior in youths with OCD
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Free arrangement task
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hand washing task
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Arrangement of objects on contrasting carpets
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Video recording methodology
Number of subjects: 39

Group type: COMPARATOR
Intervention: CY-BOCS
Number of subjects: 39
Study: 27830957

Group type: EXPERIMENTAL
Intervention: Ofatumumab plus fludarabine and cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide
Number of subjects: 0
Study: 27831501

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (mAb) therapy
Number of subjects: 199
Study: 27832753

Group type: EXPERIMENTAL
Intervention: Oxytocin augmentation
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Caesarean section
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Severe hypertensive disorders
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Blood pressure recording during active labour
Number of subjects: 388

Group type: COMPARATOR
Intervention: Overall facility-based stillbirth rate
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Foetal heart rate assessment
Number of subjects: 388
Study: 27832799

Group type: EXPERIMENTAL
Intervention: VMAT (Volumetric Modulated Arc Therapy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 3DCRT (3D Conformal Radiotherapy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: VMAT (5x5 Gy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 3DCRT (5x5 Gy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: VMAT
Number of subjects: 25

Group type: COMPARATOR
Intervention: 3DCRT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: VMAT (25x1.8 Gy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: VMAT and 3DCRT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hypofractionated schedule
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Normal life expectancy
Number of subjects: 25
Study: 27832850

Group type: EXPERIMENTAL
Intervention: CTO crossing device
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Wire-catheter approach
Number of subjects: 1006
Study: 27833752

Group type: EXPERIMENTAL
Intervention: Critical Care Pain Observation Tool (CPOT)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Behavioral Pain Scale (BPS)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combination of CPOT and BPS
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 101
Study: 27834029

Group type: EXPERIMENTAL
Intervention: Opiorphin levels in iBMS patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Blood opiorphin levels
Number of subjects: 21

Group type: COMPARATOR
Intervention: Salivary opiorphin levels
Number of subjects: 21

Group type: COMPARATOR
Intervention: Urinary opiorphin levels
Number of subjects: 21
Study: 27834663

Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Pd/Pa (distal coronary to aortic pressure ratio)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Hybrid strategy incorporating iFR or Pd/Pa
Number of subjects: 197

Group type: COMPARATOR
Intervention: FFR (fractional flow reserve)
Number of subjects: 197
Study: 27834750

Group type: EXPERIMENTAL
Intervention: Patients deemed too good for intravenous tissue-type plasminogen activator
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Age, initial National Institutes of Health Stroke Scale, and infarct location
Number of subjects: 380
Study: 27834778

Group type: EXPERIMENTAL
Intervention: Hippocampus and BF volumetry in primary care
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: White matter lesions
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hippocampus and BF volumetry
Number of subjects: 71
Study: 27835722

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole (target dose: 3 mg/d)
Number of subjects: 44
Study: 27835869

Group type: EXPERIMENTAL
Intervention: OTX015 (MK-8628)
Number of subjects: 0
Study: 27836022

Group type: EXPERIMENTAL
Intervention: LVAD therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 0
Study: 27836288

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Mixed feeding
Number of subjects: 955

Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 955
Study: 27836676

Group type: EXPERIMENTAL
Intervention: Baseline IL-6 (quarters)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Baseline IL-17F (highest quarters vs others)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Baseline IL-23 (highest quarters vs others)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Baseline IL-17A
Number of subjects: 192
Study: 27836716

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Brigatinib 90 mg once daily
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily with a 7 day lead-in at 90 mg
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 137
Study: 27836815

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help CBT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 27836860

Group type: EXPERIMENTAL
Intervention: Everolimus as primary therapy
Number of subjects: 0
Study: 27837749

Group type: EXPERIMENTAL
Intervention: Sustained inflation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation with positive end-expiratory pressure
Number of subjects: 0
Study: 27838305

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 0
Study: 27839651

Group type: EXPERIMENTAL
Intervention: SARA
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: INAS
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: SCAFI
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: ADL
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: PVF
Number of subjects: 605
Study: 27839782

Group type: EXPERIMENTAL
Intervention: 0.5mg/kg ketamine infusion
Number of subjects: 93
Study: 27839979

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with velaglucerase alfa
Number of subjects: 39
Study: 27840583

Group type: EXPERIMENTAL
Intervention: RRx-001 followed by reintroduced platinum doublets
Number of subjects: 1

Group type: COMPARATOR
Intervention: Platinum doublets
Number of subjects: 1